| Trevor N Tolman, | |
|
8901 W Lincoln Ave, West Allis, WI 53227-2409 | |
| (414) 328-6000 | |
| Not Available |
| Full Name | Trevor N Tolman |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 7 Years |
| Location | 8901 W Lincoln Ave, West Allis, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124544127 | NPI | - | NPPES |
| 100073778 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 109 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Allis Memorial Hospital | West allis, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.
Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).
WNYC's Fred Mogul, working in partnership with Kaiser Health News and NPR, writes: "As a way to reduce the number of uninsured, states are being encouraged to set more generous income limits for Medicaid as part of the Affordable Care Act. If states comply, they can get 100 percent federal funding in the first three years, declining to 90 percent funding over time. Typically, states and the federal government share the burden at a ratio that's closer to 50-50."
IMRIS Inc. (TSX: IM) today announced that it has received clearance from Australia's Therapeutic Goods Administration permitting the Company to market its newest products, IMRISNV and IMRIScardio in Australia.
› Verified 8 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.
Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).
WNYC's Fred Mogul, working in partnership with Kaiser Health News and NPR, writes: "As a way to reduce the number of uninsured, states are being encouraged to set more generous income limits for Medicaid as part of the Affordable Care Act. If states comply, they can get 100 percent federal funding in the first three years, declining to 90 percent funding over time. Typically, states and the federal government share the burden at a ratio that's closer to 50-50."
IMRIS Inc. (TSX: IM) today announced that it has received clearance from Australia's Therapeutic Goods Administration permitting the Company to market its newest products, IMRISNV and IMRIScardio in Australia.
› Verified 8 days ago
| Entity Name | Columbia St Marys Hospital Milwaukee Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073832218 PECOS PAC ID: 5890604722 Enrollment ID: O20101101000597 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.
Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).
WNYC's Fred Mogul, working in partnership with Kaiser Health News and NPR, writes: "As a way to reduce the number of uninsured, states are being encouraged to set more generous income limits for Medicaid as part of the Affordable Care Act. If states comply, they can get 100 percent federal funding in the first three years, declining to 90 percent funding over time. Typically, states and the federal government share the burden at a ratio that's closer to 50-50."
IMRIS Inc. (TSX: IM) today announced that it has received clearance from Australia's Therapeutic Goods Administration permitting the Company to market its newest products, IMRISNV and IMRIScardio in Australia.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Trevor N Tolman, Po Box 735044, Chicago, IL 60673-5044 Ph: (800) 326-2250 | Trevor N Tolman, 8901 W Lincoln Ave, West Allis, WI 53227-2409 Ph: (414) 328-6000 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.
Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).
WNYC's Fred Mogul, working in partnership with Kaiser Health News and NPR, writes: "As a way to reduce the number of uninsured, states are being encouraged to set more generous income limits for Medicaid as part of the Affordable Care Act. If states comply, they can get 100 percent federal funding in the first three years, declining to 90 percent funding over time. Typically, states and the federal government share the burden at a ratio that's closer to 50-50."
IMRIS Inc. (TSX: IM) today announced that it has received clearance from Australia's Therapeutic Goods Administration permitting the Company to market its newest products, IMRISNV and IMRIScardio in Australia.
› Verified 8 days ago
Michael James Bills, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Quinn Justine Kruel, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Cassandra A Hertrampf, C-AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Taylor S Levin, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Melissa Kaufmann, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Madeline Ann Schafer, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 |